Zyvox Safety Alert Undercuts PhRMA Good News Events
This article was originally published in RPM Report
Executive Summary
Talk about bad timing. A March 16 safety alert issued by the Food & Drug Administration regarding Pfizer Inc.'s antibiotic linezolid (Zyvox) couldn't have come at a worse time. If there was any doubt left on the point, it is gone now: drug safety will be the dominant theme for the pharmaceutical industry in 2007.
You may also be interested in...
The Agency that Cries Wolf
FDA is being more proactive about issuing safety warnings. But, as GSK's experience with Advair shows, what looks like bad news to Wall Street may not matter as much to physicians. FDA is well aware of the limitations of its risk communication techniques, but for now the agency is commited to transparency.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.